SARS-CoV-2 Antibodies

Detection and inhibition of target proteins

Sequence and structure of the coronavirus SARS-CoV-2 are well understood and appropriate targets for vaccines and therapeutics have been defined. Specific recombinant antibodies against these target proteins are an important tool for further research into the mode of action of the virus and the diverse clinical picture of COVID-19 as well as for drug and diagnostica development. With the help of our partners, we are able to offer you a wide range of specific antibodies and antibody fragments against various relevant SARS-CoV-2 antigens.

The nucleocapsid protein (N) is the most detectable protein in corona viruses. It is very immunogenic and highly conserved. The spike protein (S) on the surface of the virus envelope is essential for virus entry and an important target for antibodies and vaccines. (Walls et al., Cell 2020)

A key enzyme is nsp12 polymerase, with two cofactors essential for nucleotide polymerization, nsp7 and nsp8. (Kirchdoerfer et al., Nature 2020)

IHC-validated SARS-CoV-2 antibodies

Under our brand dianova, we offer anti-human SARS-CoV-2 spike protein monoclonal antibodies, that have been validated in infected lung tissue samples for the differentiation of spike protein subtypes by immunohistochemistry:


SARS-CoV-2 Spike S1 (DNA-IHC-184005)	SARS-CoV-2 Spike RBD (DNA-IHC-184006)

SARS-CoV-2 Spike S2 (DNA-IHC-184007)	SARS-CoV-2 Spike S1 (DNA-IHC-184008)

SARS-CoV-2 antibodies from GeneTex

Art. number	Product description
GTX635654	SARS-CoV-2 Spike S1 antibody [HL6]
GTX632604	SARS-CoV-2 Spike S2 antibody [1A9]
GTX635654	SARS-CoV-2 Spike RBD antibody [HL1004]
GTX635679	SARS-CoV-2 nucleocapsid antibody [HL344]
GTX632269	SARS-CoV / SARS-CoV-2 nucleocapsid antibody [6H3]
GTX135467	SARS-CoV-2 RdRp (nsp12) polyclonal antibody
GTX632696	SARS-CoV / SARS-CoV-2 NSP8 antibody [5A10]
GTX632602	SARS-CoV / SARS-CoV-2 ORF7a antibody [3C9]

>> Additional COVID-19 antibodies from GeneTex

Monoclonal SARS-CoV-2 antibodies from BioServ UK

Art. number	Product description
BIS-BSV-N-01-*	Elite Anti-SARS-CoV-2 Nucleocapsid Protein Mab
BIS-BSV-RBD-01-*	Elite Anti-SARS-CoV-2 Spike (S1-RBD) Mab
BIS-BSV-S1-01-*	Elite Anti-SARS-CoV-2 Spike (S1) Mab
BIS-BSV-S2-01-*	Elite Anti-SARS-CoV-2 Spike (S2) Mab

CR3022 Variants from Absolute Antibody

The anti-SARS clone CR3022 was first described in 2006. In early 2020, Tian et al. showed that the clone has a high affinity for SARS-CoV-2 (2019-nCoV). Scientists around the world are investigating this antibody as a candidate for the development of mono- and combination therapies.

Absolute Antibodies offers several engineered formats of the CR3022 clone that open up new experimental possibilities for in vitro and in vivo use, including IgG1, IgG2, IgG3, IgA, IgM, as well as human and murine Fab and Fab2 formats with His tags. Further variants are in work.

>> CR3022 recombiant Anti-SARS antibodies from Absolute Antibody